Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Morning Bell 7 February

Grady Wulff
February 7, 2024

Morning Bell 6 February

Grady Wulff
February 6, 2024

Morning Bell 5 February

Sam Kanaan
February 5, 2024

Weekly Wrap 2 February

Grady Wulff
February 2, 2024

Morning Bell 2 February

Sam Kanaan
February 2, 2024

Morning Bell 1 February

Sam Kanaan
February 1, 2024

Morning Bell 31 January

Grady Wulff
January 31, 2024

Morning Bell 30 January

Grady Wulff
January 30, 2024

Morning Bell 29 January

Grady Wulff
January 29, 2024

Morning Bell 25 January

Sam Kanaan
January 25, 2024

Morning Bell 24 January

Grady Wulff
January 24, 2024

Morning Bell 23 January

Grady Wulff
January 23, 2024